Loading
MERCK Kommanditgesellschaft auf Aktien Stock: price and insider trades · Germany
No insider purchase over the last 90 days. The latest was filed 25 Mar 2026.
MERCK Kommanditgesellschaft auf Aktien: what insiders have been doing
Every trade that managers of MERCK Kommanditgesellschaft auf Aktien disclose to BaFin is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Darmstadt, Germany. It was founded in 1668. Between 18 October 2025 and 18 October 2026, 2 insiders published 2 filings.
Only purchases show up on the open market, 2 purchases in all worth €823k, filed by 2 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 2 senior executives among the declarants. Biggest ticket of the year: €472k, bought by Röder von Diersburg, Freifrau Helene and made public on 25 March 2026 (0.0009% of market cap).
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The most recent open-market purchase was published on 25 March 2026, 206 days ago.
With 2 filings in twelve months, the company is quieter than the median of 5 filings across the 287 companies we follow on the same exchange. Over the whole record (from 2026), the tally stands at 2 purchases and no sales.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. This summary is built from BaFin disclosures alone and does not predict where the share price will go.
Insider Decl.
2
Thresholds
n/a
Buy Volume
€822,968
2 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleFreifrau Helene Röder von Diersburg2 buys
Belén Garijo Lopez1 buy
Since the insiders bought
- +36.4%Entry €105.05 · Close 15 Oct 2026 €143.25
- +36.4%Entry €105.05 · Close 15 Oct 2026 €143.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate MERCK Kommanditgesellschaft auf Aktien Buy (bullish), based on 14 analysts. Average price target: €150.00.
Fundamental score
Ranked 8,188 of 24,148 companies
59.5
score / 100
Value55
Quality65
FCF yld3.3%
Earn yld4.3%
EV/EBITDA12.1x
ROE8.1%
Gross mgn59%
Net mgn12%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€139.50
Analyst consensus
14 analystsBuy
€125.00Target €150.00(+8%)€179.00
Income statement
Revenue€21.1B
Gross profit€12.3B59% margin
EBITDA€6.0B28% margin
Net income€2.6B11.2% margin
Valuation
PER (trailing)24.0x
PER (forward)15.8x
P/Book2.0x
Beta0.81
Balance sheet & cash
Market cap€60.7B
Total debt€12.0B
Free Cash Flow€2.0B
Debt / Equity41%
Profitability & ownership
ROE8.1%
ROA4.7%
% insiders0.0%
% institutions55.5%
Last declaration on 25 March 2026
Declarations2 total
4,563.042 shares@ €103.530.0009% mcap100.0% of flowShareISIN DE0006599905BAFIN:40001134
Canonical exit: 22 Jun 2026 (T+90)
3,386.031 shares@ €103.530.0007% mcap100.0% of flowShareISIN DE0006599905BAFIN:40001134-969eea4fa8e9
Canonical exit: 22 Jun 2026 (T+90)
2 of 2 declarations
About MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien (ISIN: DE0006599905, ticker: MRK.DE) is a benchmark German listed company traded on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany. Merck positions itself as a science and technology group with three core business pillars: Life Science, Healthcare, and Electronics. Founded in 1668, it is one of Germany’s oldest industrial groups, headquartered in Darmstadt, where the company’s global decision-making center is also located. The founding family remains the long-term anchor shareholder, supporting a governance model built around continuity and strategic patience. ([merckgroup.com](https://www.merckgroup.com/de/geschaeftsbericht/2024/lagebericht/grundlagen-des-konzerns/unternehmensprofil-und-struktur.html?utm_source=openai))
Operationally, Merck spans human healthcare, tools and services for biopharma research and production, and high-performance materials for semiconductors and advanced electronics. In Healthcare, the group markets therapies and products in oncology, cardiovascular disease, metabolic disorders, and endocrinology; Erbitux remains one of the segment’s leading products by sales. Life Science serves laboratories, bioprocessing customers, and biotech manufacturers with consumables, reagents, filtration and quality-control solutions, alongside process-development services. Electronics supplies specialty materials and process solutions for displays, semiconductor manufacturing, and other high-end technology applications. ([merckgroup.com](https://www.merckgroup.com/de/geschaeftsbericht/2024/lagebericht/wirtschaftsbericht/vergleich-prognose-mit-geschaeftsverlauf.html?utm_source=openai))
Read moreShow less
Merck’s competitive position is grounded in scientific depth, global reach, and exposure to long-term growth markets. In healthcare, it competes with major global pharma groups but benefits from a focused portfolio and a strong innovation engine. In Life Science, Merck has a well-established customer base across biopharma thanks to a broad, hard-to-replicate product and services platform. Electronics is more cyclical, but it gives the group leverage to semiconductor and advanced materials demand trends. The group reported a return to growth in 2024, with consolidated revenue of EUR 21.156 billion. ([merckgroup.com](https://www.merckgroup.com/de/geschaeftsbericht/2024/lagebericht/wirtschaftsbericht/geschaeftsverlauf-und-wirtschaftliche-lage/konzern.html?utm_source=openai))
Recent headlines highlight active portfolio management. In February 2025, Merck confirmed advanced discussions regarding a potential acquisition of SpringWorks Therapeutics, underscoring its intent to deepen its Healthcare footprint. In 2024, the group also announced the divestment of Surface Solutions, with closing expected in the second half of 2025, as part of a sharpening of Electronics around more strategic businesses. At the same time, Merck continued to invest in production and R&D capabilities in Germany and South Korea, reinforcing its global industrial and innovation base. ([merckgroup.com](https://www.merckgroup.com/de/geschaeftsbericht/2024/konzernanhang/allgemeine-angaben/ereignisse-nach-dem-bilanzstichtag.html?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
